Endurant Capital Management LP purchased a new stake in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 18,837 shares of the biopharmaceutical company’s stock, valued at approximately $170,000.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Northern Trust Corp boosted its holdings in shares of Dicerna Pharmaceuticals by 6.1% in the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 2,094 shares during the period. Emerald Advisers Inc. PA purchased a new stake in shares of Dicerna Pharmaceuticals in the fourth quarter valued at approximately $266,000. EAM Investors LLC purchased a new stake in shares of Dicerna Pharmaceuticals in the fourth quarter valued at approximately $581,000. Millennium Management LLC boosted its holdings in shares of Dicerna Pharmaceuticals by 142.8% in the fourth quarter. Millennium Management LLC now owns 66,907 shares of the biopharmaceutical company’s stock valued at $604,000 after purchasing an additional 39,348 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Dicerna Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after purchasing an additional 14,517 shares during the period. Hedge funds and other institutional investors own 75.28% of the company’s stock.
Shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) opened at $12.54 on Tuesday. The firm has a market capitalization of $672.97, a price-to-earnings ratio of -3.44 and a beta of 2.18. Dicerna Pharmaceuticals Inc has a twelve month low of $2.52 and a twelve month high of $15.00.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.25). The company had revenue of $1.40 million for the quarter, compared to analysts’ expectations of $1.45 million. Dicerna Pharmaceuticals had a negative return on equity of 171.81% and a negative net margin of 2,637.15%. The business’s quarterly revenue was up 976.9% compared to the same quarter last year. analysts forecast that Dicerna Pharmaceuticals Inc will post -1.97 earnings per share for the current fiscal year.
A number of analysts recently issued reports on the company. Evercore ISI assumed coverage on Dicerna Pharmaceuticals in a report on Tuesday, January 16th. They issued an “outperform” rating and a $14.00 price target for the company. Zacks Investment Research lowered Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 9th. ValuEngine upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Stifel Nicolaus upped their target price on Dicerna Pharmaceuticals from $10.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, March 9th. Finally, Chardan Capital restated a “neutral” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $11.21.
COPYRIGHT VIOLATION NOTICE: This piece was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.thestockobserver.com/2018/03/20/endurant-capital-management-lp-purchases-shares-of-18837-dicerna-pharmaceuticals-inc-drna.html.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Want to see what other hedge funds are holding DRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dicerna Pharmaceuticals Inc (NASDAQ:DRNA).
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.